miR‑219‑3p regulates the occurrence of hepatic fibrosis by targeting Smad2

  • Authors:
    • Weihua Yin
    • Wei Zhang
    • Yanfang Zhu
    • Huihui Ni
    • Li Gong
    • Maoying Fu
  • View Affiliations

  • Published online on: April 11, 2019     https://doi.org/10.3892/etm.2019.7480
  • Pages: 4635-4642
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Abnormal expression of microRNA (miR)‑219‑3p has been widely identified in different tumors. However, whether miR‑219‑3p is involved in the progression of hepatic fibrosis (HF) has never been explored. The present study showed that compared with healthy controls, the levels of miR‑291‑3p in peripheral blood were decreased in patients with HF. Furthermore, much lower levels of miR‑291‑3p were identified in fibrotic liver tissues compared with that of normal liver tissues. Receiver operating characteristic curve analysis showed that the levels of miR‑291‑3p in peripheral blood may screen patients with HF from healthy controls. Reverse transcription quantitative polymerase chain reaction analysis showed that overexpression of miR‑291‑3p significantly suppressed the mRNA levels of Snai1, vascular endothelial‑specific cadherin (VE‑cadherin), Vimentin, transforming growth factor (TGF)‑β1, and glial fibrillary acidic protein (GFAP). The protein levels of Snai1, VE‑cadherin, Vimentin, TGF‑β1, and GFAP were also decreased in hepatic stellate cells transfected with miR‑291‑3p mimics. Further study indicated that mothers against decapentaplegic homolog 2 (Smad2) was a target gene of miR‑291‑3p. More importantly, silencing of Smad2 could abolish miR‑291‑3p inhibition‑induced TGF‑β1 signaling activation. In summary, reduced peripheral blood miR‑291‑3p may be involved in the progression of HF via targeting Smad2.
View Figures
View References

Related Articles

Journal Cover

June-2019
Volume 17 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Yin, W., Zhang, W., Zhu, Y., Ni, H., Gong, L., & Fu, M. (2019). miR‑219‑3p regulates the occurrence of hepatic fibrosis by targeting Smad2. Experimental and Therapeutic Medicine, 17, 4635-4642. https://doi.org/10.3892/etm.2019.7480
MLA
Yin, W., Zhang, W., Zhu, Y., Ni, H., Gong, L., Fu, M."miR‑219‑3p regulates the occurrence of hepatic fibrosis by targeting Smad2". Experimental and Therapeutic Medicine 17.6 (2019): 4635-4642.
Chicago
Yin, W., Zhang, W., Zhu, Y., Ni, H., Gong, L., Fu, M."miR‑219‑3p regulates the occurrence of hepatic fibrosis by targeting Smad2". Experimental and Therapeutic Medicine 17, no. 6 (2019): 4635-4642. https://doi.org/10.3892/etm.2019.7480